TriangleNCT02723994 · CITED IN SOURCE DOCUMENTS
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2026-03-11
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Eligible for study when participant is 1 year to 21 years at the time of diagnosis * Eligible Ages in Canada; 2 years to 21 years * De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present at diagnosis: * Age ≥ 10 years * White blood cell (WBC) ≥ 50 × 10\^3/μL * CNS3 leukemia at diagnosis * Systemic steroid pretreatment without presteroid WBC documentation * Diagnostic bone marrow or peripheral blood sample must have gene expression profiling and downstream genetic testing performed by submitting diagnostic specimens under the COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study. Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested by low density microarray testing at the COG ALL reference laboratory or TriCore laboratory at the University of New Mexico AND must contain 1 of the following genetic lesions: (determined at COG ALL reference laboratories, or equivalent CAP/CLIA-certified laboratories approved by the medical monitor: 1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+) 2. CRLF2 rearrangement without JAK mutation 3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions, IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as determined by a COG ALL Reference Laboratory * Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in Study AALL1131 or its successor study, or as per the institutional standard of care for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed * Male and female subjects of reproductive non childbearing potential or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participation Exclusion Criteria: * Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception of hydroxyurea or steroid pretreatment * Trisomy 21 (Down syndrome) * BCR-ABL1-rearranged (Ph+) ALL * Calculated creatinine clearance or radioisotope glomerular filtration rate \< 70 mL/min/1.73 m\^2 * Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age * Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN) * History or evidence of cirrhosis * Platelet count \< 75 × 10\^3/μL * Absolute neutrophil count (ANC) \< 750/μL * Positive screen for hepatitis B or C * Known human immunodeficiency virus infection
- healthy Volunteers
- false
- maximum Age
- 21 Years
- minimum Age
- 1 Year
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: Ruxolitinib
- Drug: Asparaginase Erwinia Chrysanthemi
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Dexamethasone
- Drug: Doxorubicin
- Drug: Leucovorin Calcium
- Drug: Mercaptopurine
- Drug: Methotrexate
- Drug: Pegaspargase
- Drug: Prednisone
- Drug: Thioguanine
- label
- Ruxolitinib in combination with chemotherapy
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- description
- In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
- name
- Ruxolitinib
- other Names
- INCB018424
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Asparaginase Erwinia Chrysanthemi
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Cyclophosphamide
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Cytarabine
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Dexamethasone
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Doxorubicin
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Leucovorin Calcium
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Mercaptopurine
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Methotrexate
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Pegaspargase
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Prednisone
- type
- DRUG
- arm Group Labels
- Ruxolitinib in combination with chemotherapy
- name
- Thioguanine
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 171
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms
- time Frame
- Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)
- measure
- Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1
- time Frame
- Part 2: assessed at 3 years
- secondary Outcomes
- measure
- Safety and tolerability of the combination treatment for subjects beginning treatment at the recommended dose for Part 2, as assessed by AEs, vital signs, clinical laboratory tests, and echocardiograms
- time Frame
- AEs assessed from screening through up to 30 days after the last dose of study treatment, expected to be 26 months (females) or 38 months (males)
Full study description
- brief Summary
- This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-88ab90481b3c44de8ec0
- requested nct id
- NCT02723994
- primary nct id
- NCT02723994
- source kind
- fda_spl_label
- source record id
- 1c261eb0-f426-47a1-8281-62282d207644
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- afe5a4f953fbfba561d42c4ca887a7a06c3d3c539a2ce70ad0e410dd2591748c
- payload
- application numbers
- NDA202192
- NDA217180
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-88ab90481b3c44de8ec0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02723994
- occurrences
- context exact
- f high-risk, de novo CRLF2 rearranged or JAK pathway–mutant Ph-like acute lymphoblastic leukemia (ALL) were assessed but not established in a single-arm trial (NCT02723994). The patients included 2 infants (age < 2 years), 42 children (age 2 to < 12 years) and 62 adolescents (age 12 to < 17 years). No new safety signals were obse
- end
- 5473
- exact text
- NCT02723994
- start
- 5462
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/95/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- 1c261eb0-f426-47a1-8281-62282d207644
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2308c7b7fbdfa5e6dad4d3f1897481fca2df7ee8401f00366c651de316bd344e
- spl effective time
- 20260720
- spl set id
- f1c82580-87ae-11e0-bc84-0002a5d5c51b
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c8c38f731e008464ced4
- requested nct id
- NCT02723994
- primary nct id
- NCT02723994
- source kind
- fda_spl_label
- source record id
- 1c261eb0-f426-47a1-8281-62282d207644
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- a818be3b9f35e70a2f7c1ff97debbb57f04bd39c9f10c1775b9e134f8a55c38c
- payload
- application numbers
- NDA202192
- NDA217180
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c8c38f731e008464ced4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02723994
- occurrences
- context exact
- f high-risk, de novo CRLF2 rearranged or JAK pathway–mutant Ph-like acute lymphoblastic leukemia (ALL) were assessed but not established in a single-arm trial (NCT02723994). The patients included 2 infants (age < 2 years), 42 children (age 2 to < 12 years) and 62 adolescents (age 12 to < 17 years). No new safety signals were obse
- end
- 2339
- exact text
- NCT02723994
- start
- 2328
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/95/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- 1c261eb0-f426-47a1-8281-62282d207644
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 17ddfc877c68d371650f52a0404a20a0e0a796f950d508062bc8434318b26af1
- spl effective time
- 20260720
- spl set id
- f1c82580-87ae-11e0-bc84-0002a5d5c51b
Preserved source evidence · Not medical advice